Patrick Ashe
Plus aucun poste en cours
Profil
Patrick Ashe is the founder of AGI Therapeutics Plc (founded in 2004), Athpharma Ltd.
(founded in 2001), and HZNP USA LLC (founded in 2011).
At AGI Therapeutics Plc, he held the title of Executive Director & SVP-Business Development from 2004 to 2011.
At Athpharma Ltd., he held the title of Senior Vice President-Business Development from 2001 to 2004.
At HZNP USA LLC, he held the title of Vice President-Corporate Development from 2011 to 2014.
Mr. Ashe's former jobs include Director at DOV Pharmaceutical, Inc. from 1999 to 2010, Director-Commercial Development at Elan Pharmaceuticals, LLC, Independent Non-Executive Director at Poolbeg Pharma Plc, Vice President-Business Development at Elan Corp.
Plc from 1994 to 2001, and Senior Vice President-Business Development at Horizon Therapeutics Plc.
Mr. Ashe received his undergraduate degree from University College Dublin in 1985 and his MBA from DCU Business School in 1994.
Anciens postes connus de Patrick Ashe
| Sociétés | Poste | Fin |
|---|---|---|
| POOLBEG PHARMA PLC | Directeur/Membre du Conseil | 30/11/2023 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01/01/2016 |
HZNP USA LLC
 HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | Fondateur | 01/01/2014 |
AGI Therapeutics Plc
 AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | Fondateur | 01/01/2011 |
DOV Pharmaceutical, Inc.
 DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Directeur/Membre du Conseil | 22/07/2010 |
Formation de Patrick Ashe
| University College Dublin | Undergraduate Degree |
| DCU Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| POOLBEG PHARMA PLC | Health Technology |
| Entreprise privées | 7 |
|---|---|
Elan Corp. Plc
 Elan Corp. Plc Pharmaceuticals: MajorHealth Technology Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland. | Health Technology |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | Commercial Services |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
| Athpharma Ltd. | Commercial Services |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | Health Technology |
